SC
GPCR icon

Stempoint Capital’s Structure Therapeutics GPCR Stock Holding History

Stempoint Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Sell
38,178
-162,089
-81% -$7.17M 0.35% 63
2026
Q1 		$9.65M Sell
200,267
-150,806
-43% -$10.3M 1.85% 16
2025
Q4 		$24.4M Buy
351,073
+221,738
+171% +$9.05M 4.19% 5
2025
Q3 		$3.62M Buy
+129,335
New +$2.58M 0.73% 36

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Stempoint Capital's GPCR Position: Q2 2026 in Review

Stempoint Capital reduced its Structure Therapeutics (GPCR) stake by 81% in Q2 2026, selling an estimated $7.17M and leaving 38,178 shares worth $2.05M. The position accounts for 0.35% of the portfolio, ranked #63.

Stempoint Capital first reported a position in GPCR in Q3 2025 and has held it in 4 quarters since. The position peaked at $24.4M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Stempoint Capital held 38,178 shares of Structure Therapeutics worth $2.05M as of Q2 2026.
  • Stempoint Capital sold 162,089 Structure Therapeutics shares in Q2 2026, an estimated $7.17M.
  • Structure Therapeutics made up 0.35% of Stempoint Capital's portfolio in Q2 2026, its #63 holding.
  • Stempoint Capital first reported a position in Structure Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Stempoint Capital's Structure Therapeutics position peaked at $24.4M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.